Company news: Onyx, Novartis

Share this article:
The FDA gave an expedited approval for Onyx's multiple myeloma drug Kyprolis Monday, based on a Phase 2b study of 266 patients. The injection was approved as a third line defense for patients who have failed to respond to at least two other therapies and have had their condition progress within 60 days of their last treatment.

The latest FDA approval in the breast cancer wars may now come with the question “marshmallow or whipped cream.” Novartis announced Friday that its drug Afinitor got the OK for use in women with advanced hormone receptor positive 2 breast cancer in post-menopausal women, if the disease progresses after patients have been on letrozole or anastrozole. Afinitor is taken along with exemestane. Bloomberg reported women were taking the drug off-label, and said patients navigated one of the common side effects – sores on the tongue – by enveloping tablets in marshmallows or whipped cream. The company said in a statement that a double-blind study of 724 women was part of the FDA's grounds for approval. The study said treatment stalled progression for 7.8 months compared to 3.2 months with exemestane alone.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.